The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Mice with diabetes induced by streptozotocin, plus controls; numbers not stated in the abstract
- Dose used in the study
- Micronised palmitoylethanolamide 10 mg/kg daily by oral gavage, starting 2 weeks after streptozotocin
- Duration
- To 16 weeks
- What was measured
- Mechanical and thermal hyperalgesia, motor function, mast cell activation, nerve growth factor, nerve histology, oxidative and nitrosative stress, cytokines, angiogenesis, apoptosis, spinal microglia, p38 MAPK and NF-kappa-B, and PPAR-alpha involvement.
What the authors reported
This laboratory study found:
- Micronised PEA reduced mechanical and thermal hyperalgesia and motor changes, and lowered mast cell activation and nerve growth factor.
- It reduced nerve damage, oxidative and nitrosative stress, cytokines, angiogenesis and apoptosis, and inhibited spinal microglial activation, phospho-p38 and NF-kappa-B.
- The authors link the effects at least in part to PPAR-alpha.
Limits of this study
A mouse model of diabetic neuropathy; it cannot show effect in people. Animal numbers are not in the abstract. Conflicts not stated in the record, though this Messina group has worked with Epitech, which makes micronised PEA.
Source
PubMed 31344333 · doi:10.1096/fj.201900538R
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.